How to buy BrainsWay (BWAY) stock

BrainsWay Ltd is a diagnostics & research business based in the US. BrainsWay shares (BWAY) are listed on the NASDAQ and all prices are listed in US Dollars. BrainsWay employs 100 staff and has a trailing 12-month revenue of around 0.00.

BrainsWay stock price (NASDAQ: BWAY)

Use our graph to track the performance of BWAY stocks over time.

BrainsWay shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$11.14
52-week range	$5.55 - $11.77
50-day moving average	$10.26
200-day moving average	$9.25
Wall St. target price	$14.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.03

Buy BrainsWay shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BrainsWay stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BrainsWay Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BrainsWay price performance over time

Historical closes compared with the close of $11.14 from 2021-05-28

1 week (2021-07-14)	N/A
1 month (2021-06-25)	9.00%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

BrainsWay financials

Revenue TTM	$24 million
Gross profit TTM	$18.1 million
Return on assets TTM	-2.59%
Return on equity TTM	-11.34%
Profit margin	-19.44%
Book value	$4.95
Market capitalisation	$149.9 million

TTM: trailing 12 months

Shorting BrainsWay shares

There are currently 59,683 BrainsWay shares held short by investors – that's known as BrainsWay's "short interest". This figure is 29.9% down from 85,095 last month.

There are a few different ways that this level of interest in shorting BrainsWay shares can be evaluated.

BrainsWay's "short interest ratio" (SIR)

BrainsWay's "short interest ratio" (SIR) is the quantity of BrainsWay shares currently shorted divided by the average quantity of BrainsWay shares traded daily (recently around 28152.358490566). BrainsWay's SIR currently stands at 2.12. In other words for every 100,000 BrainsWay shares traded daily on the market, roughly 2120 shares are currently held short.

However BrainsWay's short interest can also be evaluated against the total number of BrainsWay shares, or, against the total number of tradable BrainsWay shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BrainsWay's short interest could be expressed as 0% of the outstanding shares (for every 100,000 BrainsWay shares in existence, roughly 0 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable BrainsWay shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BrainsWay.

Find out more about how you can short BrainsWay stock.

BrainsWay share dividends

We're not expecting BrainsWay to pay a dividend over the next 12 months.

BrainsWay share price volatility

Over the last 12 months, BrainsWay's shares have ranged in value from as little as $5.55 up to $11.767. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BrainsWay's is 0.8698. This would suggest that BrainsWay's shares are less volatile than average (for this exchange).

BrainsWay overview

Brainsway Ltd. , a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. .

Frequently asked questions

What percentage of BrainsWay is owned by insiders or institutions?
Currently 4.601% of BrainsWay shares are held by insiders and 41.179% by institutions. How many people work for BrainsWay?
Latest data suggests 100 work at BrainsWay. When does the fiscal year end for BrainsWay?
BrainsWay's fiscal year ends in December. Where is BrainsWay based?
BrainsWay's address is: Bynet Building, Jerusalem, Israel, 9777518 What is BrainsWay's ISIN number?
BrainsWay's international securities identification number is: US10501L1061 What is BrainsWay's CUSIP number?
BrainsWay's Committee on Uniform Securities Identification Procedures number is: 10501L106